Association of resection type, nodal evaluation, and survival in early-stage lung squamous cell carcinoma Authors: Evelyn Alexander, Titilope Sandra Saheed, Ahmed Elkamel, Shamele Battan-Wraith, Chiu-Hsieh Hsu, Jonathan Rice, Stephanie Worrell, Praveen Sridhar Published: 2026 ABSTRACT BackgroundWhile recent trials suggest sublobar resection is non-inferior to lobectomy for stage IA non-small cell lung cancer (NSCLC), patients with squamous cell carcinoma (SCC) were underrepresented. We aimed to evaluate outcomes of sublobar resection versus lobectomy in early-stage SCC.MethodsUsing the National Cancer Database (NCDB; 2010–2022), we identified patients >18 years with stage IA SCC. We compared demographics, tumor characteristics, perioperative outcomes, nodal evaluation, and survival between patients undergoing lobectomy or sublobar resection. Overall survival was evaluated using Kaplan-Meier analysis and Cox proportional hazards regression, with sequential adjustment for lymph node evaluation to assess its influence on survival estimates.ResultsAmong 207 patients, 63% underwent lobectomy and 37% sublobar resection. The sublobar group was older (72.0 vs. 69.2 years, P=0.006); other factors were similar. Fewer lymph nodes were examined in sublobar cases (1 vs. 9, P<0.001). Although not statistically significant, survival trended lower with sublobar resection (hazard ratio 1.57, 95% confidence interval: 0.91–2.72, P=0.10; median survival 4.1 vs. 8.6 years).ConclusionsAlthough overall survival appeared higher following lobectomy, this association was attenuated after adjustment for lymph node evaluation and was no longer statistically significant. These findings highlight the importance of adequate nodal assessment and should be considered hypothesis-generating. Highlight box Key findings • Among 207 patients with early-stage lung squamous cell carcinoma (SCC), sublobar resection was associated with fewer examined lymph nodes and worse overall survival after adjustment for patient characteristics. However, the survival difference was attenuated and no longer statistically significant after accounting for lymph node evaluation. What is known and what is new? • Randomized trials support sublobar resection for carefully selected patients with small, peripheral stage IA non-small cell lung cancer. However, patients with SCC were underrepresented, limiting the applicability of these findings to this histologic subtype. • This study specifically examined patients with early-stage SCC. Lobectomy was associated with a higher median lymph node yield than sublobar resection (9 vs. 1). After adjustment for nodal evaluation, the association between sublobar resection and mortality decreased and was no longer statistically significant. What is the implication, and what should change now? • Adequate nodal evaluation should be prioritized regardless of the extent of lung resection. These retrospective findings should be considered hypothesis-generating and support further prospective, histology-specific evaluation of sublobar resection in patients with SCC. Introduction Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers worldwide (1). NSCLC includes two primary histological subtypes: adenocarcinoma, which constitutes about 50–60% of cases, and squamous cell carcinoma (SCC), representing roughly 20–30% (2,3). Given the prevalence of NSCLC, SCC alone is still among the most prevalent and deadly cancers for men and women. SCC is closely linked with tobacco use and often arises in a central location. Despite advances in treatment, many patients with NSCLC face recurrence within 5 years (4). Surgical resection remains the mainstay of treatment for stage IA disease (5). The optimal surgical approach—lobectomy versus sublobar resection—for early-stage lung SCC is a topic of controversy. While lobectomy has been considered the standard of care for resection of early-stage NSCLC, the randomized controlled trials Japan Clinical Oncology Group (JCOG) 0802 and the Cancer and Leukemia Group B (CALGB) 140503 suggest that sublobar resection may provide oncologic outcomes comparable to lobectomy in carefully selected patients with peripheral clinical T1N0 NSCLC measuring 2 cm or less (3). Unfortunately, SCC was underrepresented in these studies, comprising only 17.9% of the patient cohort in CALGB140503, leaving uncertainty about the ability to compare the benefits of lobectomy versus sublobar resection for this specific subtype (6). Furthermore, SCC is both staged and treated differently in other organ systems, such as the esophagus and the bladder, and treatment is often tailored to histology. Despite its prevalence, SCC of the lung is staged and managed identically to adenocarcinoma. In this study, we conducted a retrospective analysis of the National Cancer Database (NCDB) comparing outcomes between sublobar resection and lobectomy in early-stage squamous cell lung cancer. We hypothesized that sublobar resection may be inferior to lobar resection in patients with SCC. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0898/rc). Methods Data source This retrospective cohort study used data from the NCDB. The NCDB is a clinical oncology database sourced from hospital registry data collected at more than 1,500 Commission on Cancer (CoC)-accredited facilities. These data are used to analyze and track patients with malignant neoplastic diseases, their treatments, and outcomes (7). This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Because the NCDB comprises exclusively deidentified patient information and does not constitute human subjects research as defined under the Common Rule (45 CFR 46), this study was deemed exempt from institutional review board review, and the requirement for informed consent was waived. All analyses were performed in accordance with the terms of the NCDB Participant User File data use agreement. Study design and patient selection The NCDB was queried for patients with early-stage (tumor less than 2 cm and node-negative across the American Joint Committee on Cancer (AJCC) 7th and 8th edition staging for NSCLC) lung SCC who underwent either lobectomy or sublobar resection from January 2010 to December 2022. Patients over 18 years old with a confirmed diagnosis of early-stage SCC were included. Patients were included based on clinical staging as node-negative, as recorded in the NCDB. Although specific staging modalities are not captured within the database, standard preoperative staging during the study period generally included chest computed tomography (CT), positron emission tomography-computed tomography (PET-CT), and invasive mediastinal staging when clinically indicated. However, a small subset was found to have occult nodal involvement on final pathology, which was retained in the analysis to reflect real-world surgical outcomes. Exclusions were made for patients who had incomplete data on survival outcomes. Cases were stratified by the type of surgical resection: lobectomy or sublobar resection (including wedge resection and segmentectomy). Among 30,677 adult patients with SCC identified in the NCDB between 2010 and 2022, 1,119 underwent lobectomy, segmentectomy, or wedge resection. Application of T1abN0M0 eligibility criteria resulted in a final study cohort of 207 patients. This yielded a cohort of 207 patients, with 130 undergoing lobectomy and 77 undergoing sublobar resection (Figure 1). Clinical staging variables were harmonized across AJCC editions using NCDB-provided clinical T-stage fields. Cases coded as T1, T1a, T1b, or T1mi were included if they satisfied study eligibility criteria. Cohort derivation from the NCDB. Among 30,677 adult patients with lung squamous cell carcinoma identified in the NCDB between 2010 and 2022, 1,119 underwent lobectomy, segmentectomy, or wedge resection. After application of clinical T1abN0M0 eligibility criteria, 207 patients were included in the final analytic cohort: 130 underwent lobectomy and 77 underwent sublobar resection, including 59 wedge resections and 18 segmentectomies. NCDB, National Cancer Database. Data collection Patient demographics, tumor characteristics, surgical approach, perioperative outcomes (e.g., length of stay, positive lymph node count, surgical margin status, and 30-day readmission rates), and long-term survival data were extracted. To control for potential confounding variables, additional data were collected on Charlson-Deyo comorbidity scores, socioeconomic status, insurance type, and facility characteristics. Statistical analysis Comparative analysis of demographic and clinical characteristics was performed using Wilcoxon rank-sum tests for continuous variables and chi-squared tests for categorical variables. For patients diagnosed between 2010 and 2020, survival outcomes were analyzed using Kaplan-Meier survival estimates and Cox proportional hazards models, adjusting for age, sex, Charlson-Deyo score, and year of diagnosis. Due to the lack of survival data, patients from 2021 were excluded from the survival analysis. Missing data were handled using available-case analysis. No imputation was performed. Variables with missing observations are reported in the corresponding tables. Logistic regression was employed for binary outcomes such as 30-day readmission, while Poisson regression analyzed count data (e.g., number of lymph nodes examined). All tests were two-sided with a significance threshold of P<0.05. Because extent of nodal evaluation is influenced by procedure type, lymph node variables may function as mediators rather than simple confounders. Models including nodal variables were therefore interpreted as estimating the association between procedure type and survival independent of differences in nodal assessment. Exploratory analyses comparing wedge resection and segmentectomy separately were performed to assess heterogeneity within the sublobar cohort. Detailed results are presented in Tables S1-S3 and Figure S1. Results Patient characteristics The cohort consisted of 207 patients, with the majority White (93.7%) and a slight male predominance (54.1%). The mean age for the overall cohort was 70.2±7.7 years with most patients having Medicare (72.5%) and Charlson-Deyo score of 0 (54.1%). Overall, 62.8% (n=130) underwent lobectomy and 37.2% (n=77) underwent sublobar resection. Most sublobar resections were wedge resections (76.6%, n=59) while nearly one quarter were segmentectomies (23.4%, n=18). Patients in the sublobar group were significantly older (mean age 72.0 vs. 69.2 years, P=0.006). There were no statistically significant differences between the groups in terms of sex, race, socioeconomic status, or Charlson-Deyo scores. The overall cohort was comprised of patients with clinical stage T1a in 64.7% (n=134) of cases and T1b in 29.9% (n=62) of cases, with no statistically significant differences across the groups (P=0.28) (Table 1). Table 1Summary of patient and tumor characteristics by procedure typeVariableOverall (N=207)Lobectomy (N=130)Sublobar (N=77)P valueAge, years70.2±7.769.2±7.172.0±8.30.006Sex (male)112 (54.11)71 (54.62)41 (53.25)0.96Race0.44 Non-White11 (5.31)5 (3.85)6 (7.79) White194 (93.72)124 (95.38)70 (90.91)Ethnicity0.24 Non-Hispanic199 (96.14)125 (96.15)70 (96.10) Hispanic3 (1.45)3 (2.31)1 (1.30) Unknown5 (2.41)2 (1.54)3 (3.90)Insurance status>0.99 No4 (1.93)3 (2.31)1 (1.30) Private36 (17.39)23 (17.69)13 (16.88) Medicaid11 (5.31)7 (5.38)4 (5.19) Medicare150 (72.46)93 (71.54)57 (74.03) Government3 (1.45)2 (1.54)1 (1.30)Charlson-Deyo score0.97 0112 (54.11)69 (53.08)43 (55.84) 157 (27.54)36 (27.69)21 (27.27) 221 (10.14)14 (10.77)7 (9.09) ≥317 (8.21)11 (8.46)6 (7.79)Type of sublobar resection Segmentectomy18 (23.38)NA18 (23.38) Wedge resection59 (76.62)NA59 (76.62)Clinical T stage0.28 T110 (4.83)7 (3.13)3 (3.90) T1a134 (64.73)78 (60.00)56 (72.73) T1b62 (29.95)44 (33.85)18 (23.38) T1mi1 (0.48)1 (0.77)0 (0.00)Path T Stage I154 (74.40)94 (72.31)60 (78.00) II30 (14.49)20 (15.38)10 (12.91) III/IV13 (6.28)8 (6.15)5 (6.49) Unknown10 (4.83)8 (6.15)2 (2.60)Facility type0.79 Academic59 (28.50)36 (27.69)23 (29.87) Community94 (45.41)58 (44.62)36 (46.75) Integrated54 (26.09)36 (27.69)18 (23.38)Distance to facility29.88±77.3836.78±95.3817.72±18.250.27Year of diagnosis0.51 201017 (8.21)8 (6.15)9 (11.69) 201118 (8.70)10 (7.69)8 (10.39) 201214 (6.76)9 (6.92)5 (6.49) 201313 (6.28)10 (7.69)3 (3.9) 201413 (6.28)7 (5.38)6 (7.79) 201521 (10.14)11 (8.46)10 (12.9) 201621 (10.14)17 (13.08)4 (5.19) 201723 (11.11)17 (13.08)6 (7.79) 20185 (2.42)3 (2.31)2 (2.60) 201923 (11.11)12 (9.23)11 (14.29) 202013 (6.28)10 (7.69)3 (3.9) 202115 (7.25)9 (6.92)6 (7.79) 202211 (5.31)7 (5.38)4 (5.19)Continuous variables were summarized as mean ± standard deviation and compared using the Wilcoxon rank-sum test; categorical variables were summarized as frequency (%) and compared using the chi-squared test. The T1 category represents tumors coded as T1 without further subclassification in the NCDB. NA, not applicable; NCDB, National Cancer Database. Summary of patient and tumor characteristics by procedure type Continuous variables were summarized as mean ± standard deviation and compared using the Wilcoxon rank-sum test; categorical variables were summarized as frequency (%) and compared using the chi-squared test. The T1 category represents tumors coded as T1 without further subclassification in the NCDB. NA, not applicable; NCDB, National Cancer Database. Surgical outcomes Patients undergoing lobectomy had a higher median number of lymph nodes examined (9 vs. 1, P<0.001). Positive lymph node rates were similar across groups, with 7.9% (n=10) in the lobectomy group and 6.4% (n=3) in the sublobar group (P=0.39). Surgical margin positivity was higher in the sublobar group (5.5%) than in the lobectomy group (3.1%, P=0.28). Additionally, 30-day readmission rates were similar, but trended toward higher for the lobectomy group (6.9% vs. 2.6%, P=0.29) (Table 2). Table 2Summary of the outcomes by procedure typeVariableLobectomy (N=130)Sublobar (N=77)P valueHospital LOS (days)5.0 (3.0, 8.0)3.0 (2.0, 5.0)<0.001Number of LN examined9.00 (5.00, 15.00)1.00 (0.00, 5.00)<0.001Number of positive LN0.39 0116 (92.06)44 (93.62) 16 (4.76)3 (6.38) 22 (1.59)0 (0.00) 32 (1.59)0 (0.00)Positive margin4 (3.1)4 (5.41)0.2830-day readmission9 (6.98)2 (2.63)0.29Overall survival (patients alive at last follow-up)73 (59.35)26 (35.62)0.10Continuous variables were summarized as median (interquartile range) and categorical variables were summarized as frequency (%). Log-normal regression was performed for LOS. Poisson regression was performed for the number of LN examined. Logistic regression was performed for any positive LN, positive margin, and 30-day readmission. Cox regression was performed for overall survival. Age, sex, Charlson-Deyo score, and year of diagnosis were controlled in the adjusted analyses. Number of LN examined, and number of positive lymph nodes were also adjusted in Cox regression for overall survival. LN, lymph node; LOS, length of stay. Summary of the outcomes by procedure type Continuous variables were summarized as median (interquartile range) and categorical variables were summarized as frequency (%). Log-normal regression was performed for LOS. Poisson regression was performed for the number of LN examined. Logistic regression was performed for any positive LN, positive margin, and 30-day readmission. Cox regression was performed for overall survival. Age, sex, Charlson-Deyo score, and year of diagnosis were controlled in the adjusted analyses. Number of LN examined, and number of positive lymph nodes were also adjusted in Cox regression for overall survival. LN, lymph node; LOS, length of stay. Because wedge resections comprised the majority of sublobar procedures, exploratory analyses were performed separating wedge resection and segmentectomy. Segmentectomy was not associated with significantly different overall survival (OS) compared with lobectomy, whereas wedge resection demonstrated worse survival in unadjusted and inverse probability of treatment weighting (IPTW) analyses. However, this association was attenuated after adjustment for lymph node variables. Detailed results are provided in Tables S1-S3. Survival outcomes OS was higher in the lobectomy group with a 5-year survival rate of 59.4% compared to 35.6% in the sublobar group (P=0.10) (Table 2). Cox regression analysis, adjusted for confounding factors, including as age, sex, Charlson-Deyo score, and year of diagnosis, showed that sublobar resection was associated with a higher risk of mortality [hazard ratio (HR) 2.1, 95% confidence interval (CI): 1.41–3.14, P=0.003] (Table 3). However, when further adjusting for the number of lymph nodes examined and the number of positive lymph nodes, the statistical significance for OS diminished (HR 1.57, 95% CI: 0.91–2.72, P=0.10). Additionally, the median OS was 8.6 years for lobectomy and 4.1 years for sublobar resection. Kaplan-Meier analysis demonstrated separation of the survival curves favoring lobectomy; however, this difference was attenuated and no longer statistically significant in the fully adjusted model (Figure 2). Median survival estimates stratified by lobectomy, segmentectomy, and wedge resection are presented in Table S4. Table 3Comparisons of the outcomes between procedure types (sublobar vs. lobectomy)PredictorUnivariateMultivariateUnadjusted RR/OR/HR95% CIP valueAdjusted RR/OR/HR95% CIP valueHospital LOS0.680.55–0.840.0040.700.57–0.870.001Number of LN examined0.310.27–0.36<0.00010.310.27–0.36<0.0001Positive margin1.790.41–7.760.422.410.48–12.810.2830-day readmission0.360.05–1.450.200.390.05–1.920.29Overall survival2.101.41–3.140.0031.570.91–2.720.10Log-normal regression was performed for LOS. Poisson regression was performed for the number of LN examined. Logistic regression was performed for positive margin, 30-day readmission. Cox regression was performed for overall survival. Overall survival represents patients alive at last follow-up. Age, sex, Charlson-Deyo score ≥2 and year of diagnosis were controlled in the adjusted analyses. Number of LN examined, and number of positive lymph nodes were also adjusted in Cox regression for overall survival. CI, confidence interval; HR, hazard ratio; LN, lymph node; LOS, length of stay; OR, odds ratio; RR, rate ratio. Comparisons of the outcomes between procedure types (sublobar vs. lobectomy) Log-normal regression was performed for LOS. Poisson regression was performed for the number of LN examined. Logistic regression was performed for positive margin, 30-day readmission. Cox regression was performed for overall survival. Overall survival represents patients alive at last follow-up. Age, sex, Charlson-Deyo score ≥2 and year of diagnosis were controlled in the adjusted analyses. Number of LN examined, and number of positive lymph nodes were also adjusted in Cox regression for overall survival. CI, confidence interval; HR, hazard ratio; LN, lymph node; LOS, length of stay; OR, odds ratio; RR, rate ratio. Kaplan-Meier curves demonstrating overall survival in patients with early-stage SCC by procedure type (lobectomy versus sublobar resection). Hazard ratios shown reflect the fully adjusted Cox model including age, sex, Charlson-Deyo score, year of diagnosis, number of lymph nodes examined, and number of positive lymph nodes. CI, confidence interval; HR, hazard ratio; SCC, squamous cell carcinoma. Discussion This study compared the outcomes of lobectomy versus sublobar resection for patients with early-stage lung SCC. While lobectomy initially appeared to have a survival advantage after adjusting for patient factors, this difference lost statistical significance when accounting for variability in surgical practices, particularly lymph node sampling. However, despite not reaching statistical significance, the observed survival difference remains clinically relevant. Sublobar resection has historically been the preferred approach for patients with borderline pulmonary function or significant comorbidities due to its less invasive nature. It has gained favorability in light of the results of CALGB140503 as well as the JCOG0802. While our findings do not contradict recent CALGB data, they suggest a potential association worth further investigation, especially considering the biological and behavioral differences between squamous and nonsquamous cancers in other organ systems (8,9). Notably, in this study, patients undergoing lobectomy had nearly twice the median survival compared to those undergoing sublobar resection. This disparity may be due, in part, to the more extensive lymph node sampling associated with lobectomy, which may influence survival outcomes by allowing more accurate pathologic staging and potentially influencing postoperative management. The diminished statistical significance of survival differences after adjusting for lymph node sampling supports the hypothesis that staging quality, rather than resection type alone, may be the key driver of outcomes in early-stage SCC. These findings are consistent with CALGB140503, where sublobar resection with intraoperative nodal assessment resulted in comparable outcomes. However, unlike the well-controlled CALGB and JCOG studies, our dataset was limited by inconsistencies in lymph node sampling, preventing a definitive assessment of survival differences. While these recent large-scale studies have demonstrated the non-inferiority of sublobar resection in early-stage NSCLC, those studies were significantly limited in their representation of SCC patients, with a proportion of SCC patients not representative of the general population. SCC is a distinctly different histopathology from adenocarcinoma, with a higher propensity for lymphatic spread and often taking a more central location. Despite its distinct behavior, SCC has not been distinguished in its response to surgical therapy (10-12). Consistent with prior population-based studies, such as those by Shao et al., lobectomy was associated with improved survival compared with sublobar resection in selected patients with SCC (13). A critical finding in this study is the role of lymph node sampling, which was notably more comprehensive in the lobectomy group. The particularly low nodal yield observed among wedge resections likely reflects variability in intraoperative nodal assessment accompanying non-anatomic resections. The median number of lymph nodes examined was nine in the lobectomy group compared to one in the sublobar group, a disparity that could account for the differences in survival. Thorough lymph node sampling is crucial for detecting occult nodal disease, which can significantly influence treatment decisions. Since PET-CT and CT alone may not always identify lymph node involvement, ensuring comprehensive initial sampling is essential for accurate staging and optimal patient care (14). This aligns with the American Association for Thoracic Surgery (AATS) guidelines, which emphasize the importance of lymphadenectomy in early-stage NSCLC, including SCC, for accurate staging and improved survival outcomes (15). Recent analyses evaluating CoC nodal quality standards have similarly demonstrated associations between guideline-concordant lymph node assessment and improved oncologic outcomes after lung resection (16). Studies, such as those by David et al., demonstrated that sampling fewer than 10 lymph nodes was associated with poorer OS in surgically resected NSCLC, further supporting the importance of thorough lymph node evaluation (17). More recently, Rocco et al. reported that adherence to contemporary lymph node evaluation standards was associated with improved staging quality in patients undergoing resection for clinical stage IA NSCLC, including SCC, further emphasizing the importance of adequate nodal assessment (18). The importance of lymphadenectomy in SCC aligns with existing literature suggesting that better staging and potential removal of occult nodal disease can significantly affect long-term survival outcomes. An exploratory analysis separating wedge resection and segmentectomy further highlighted the potential importance of nodal evaluation. While survival following segmentectomy was not significantly different from lobectomy, wedge resection was associated with worse survival in unadjusted and IPTW analyses. Notably, this association was attenuated after adjustment for lymph node variables. In addition, wedge resection was associated with the lowest nodal yield among the surgical approaches evaluated. Although limited by sample size, these findings suggest that differences in nodal assessment may contribute to the observed survival differences and that grouping all sublobar resections together may obscure important distinctions between anatomical and non-anatomical resections (Tables S1-S3). The study’s findings underscore the importance of considering histology-specific characteristics, including patterns of lymphatic spread, tumor location, and recurrence risk, when planning the surgical approach for early-stage SCC. Although unadjusted analyses favored lobectomy, the observed survival difference was substantially attenuated after accounting for lymph node evaluation. This makes lobectomy a strong option for patients who are fit for surgery, as it provides a more complete resection that may reduce recurrence risk. However, SCC patients often present with comorbidities like older age or compromised lung function, which may make lobectomy too risky (19,20). For these patients, sublobar resection remains a viable alternative, especially when paired with vigilant follow-up and potential adjuvant therapies to address the higher recurrence risk. The present findings do not establish that SCC requires a different surgical approach than adenocarcinoma but suggest that histology-specific investigations may be warranted. Although positive margins were uncommon, rates were numerically higher after sublobar resection. Because recurrence data are unavailable within the NCDB, the effect of margin status on local control could not be assessed. For instance, Maeda et al. demonstrated that stage IA SCC patients had a higher rate of 5-year locoregional recurrence compared to adenocarcinoma (83% vs. 91%, respectively; P<0.001), necessitating more aggressive surgical approaches and thorough lymph node dissection (12). Multidisciplinary collaboration among surgeons, pulmonologists, and oncologists is critical to developing individualized treatment plans that account for tumor biology and patient health. For patients with higher surgical risks, this approach enables the exploration of adjunct therapies and closer follow-up to optimize outcomes. Limitations This study has several limitations, primarily related to its retrospective design and limited sample size. As a retrospective study, our findings rely on the accuracy of recorded data, and missing data points may have impacted our analysis. This design also introduces selection bias. Additionally, the NCDB does not capture pulmonary function testing, frailty measures, performance status, tumor location, or surgeon-reported rationale for procedure selection. Therefore, intentional oncologic sublobar resections cannot be distinguished from procedures performed because of limited physiologic reserve. While adjustments were made for confounders like age and comorbidities, prospective randomized studies are needed to confirm these findings specifically for SCC. The inclusion of patients with unexpected nodal positivity may have introduced heterogeneity in outcomes, though this reflects clinical reality where nodal disease is sometimes underappreciated preoperatively. Residual confounding and confounding by indication remain important limitations. The sample size may be insufficient for detecting smaller effect sizes, particularly in subgroup analyses. Also, the NCDB lacks disease-specific survival data, limiting the distinction and exclusion of patients who die from other causes in the survival analysis. Furthermore, the absence of data on adjuvant therapies, which might affect survival outcomes, is another limitation, suggesting that future studies should incorporate this variable to better understand its impact on post-surgical prognosis. Furthermore, the NCDB does not collect recurrence data. As a result, recurrence-free survival and local recurrence patterns could not be evaluated, limiting our ability to assess the oncologic significance of margin status or determine whether differences in local control contributed to survival outcomes. OS was therefore used as the primary endpoint. Additionally, the NCDB does not reliably distinguish preoperative histologic diagnosis from final pathologic diagnosis; therefore, the proportion of patients with biopsy-confirmed SCC prior to surgery could not be determined. Perhaps the single most important takeaway from these data are that we should be careful to assume that distinct oncologic entities, such as squamous cell and adenocarcinoma of the lung, behave and respond to therapy in the same way. We have learned that this assumption is incorrect when comparing squamous and nonsquamous histologies in other solid tumors and have adjusted accordingly. Esophageal squamous cell cancer is staged and approached differently than adenocarcinoma. SCC of the bladder carries a prognosis much different from urothelial cell cancer. Among all these squamous entities, NSCLC remains both highly prevalent and deadly. As our therapies become highly personalized, we should be sure to extend that personalization to tumor histology. We must look both within our institutional experiences and our population-based datasets to better delineate the behavior and success of our therapies in squamous cell lung cancer. Such research would enhance our understanding of optimal treatment pathways for early-stage SCC and help refine surgical recommendations based on patient-specific factors and tumor biology. Conclusions In this national database analysis of early-stage SCC, observed survival differences between lobectomy and sublobar resection were substantially attenuated after accounting for lymph node evaluation. Ultimately, these findings highlight the importance of adequate surgical staging and nodal assessment and should be considered hypothesis-generating. This uncertainty highlights the need for further research and a patient-centered approach that considers individual risks, tumor characteristics, and long-term outcomes. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0898/prf